Evaluating a clinical care pathway for the screening, diagnosis and treatment of fatty liver disease among primary care patients
| ISRCTN | ISRCTN46342829 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN46342829 |
| Secondary identifying numbers | EU-989-5753 |
- Submission date
- 11/05/2020
- Registration date
- 27/05/2020
- Last edited
- 22/02/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Plain English summary of protocol
Background and study aims
Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) are important clinical issues that have not received prompt attention from GPs. Although GPs are central to the identification and management of NAFLD, they seldom address the risk of advanced fibrosis in patients with frequent NAFLD comorbid conditions, including obesity, type 2 diabetes mellitus and dyslipidemia. European clinical practice guidelines suggest the use of non-invasive tests to improve the early detection of advanced fibrosis and reduce unnecessary referrals. While strong collaboration between primary and speciality care is necessary for the effective diagnosis and management of NASH, respective pathways are currently limited. There is, as such, a need to establish and evaluate easily implementable, multidisciplinary, patient-centered models to enhance primary care screening and linkage to specialty care for high-risk NAFLD/NASH patients, to inform policies and drive decisions. Such models need to be evidence-informed and theory-driven, incorporating concepts of ‘risk perception’ and ‘health literacy’, which can affect health behavior and information communication. The aim of this study is to evaluate the impact of an evidence-informed and locally adapted NASH Model of Care implemented by trained healthcare providers in increasing the numbers of patients screened for and diagnosed with NAFLD/NASH in primary care and linkage to specialty care compared to usual care.
Who can participate?
Adults who have at least one of the following conditions, including metabolic dysfunction, liver dysfunction, NAFLD or cardiovascular disease.
What does the study involve?
A total of 12 primary care practices, four from each country (Greece, Spain), are randomly assigned (like the toss of a coin) to either the NAFLD/NASH Model of Care group or the control group. All GPs in the NASH Model of Care group will receive the NAFLD/NASH training intervention and be supported in implementing it. The NAFLD/NASH Model of Care includes criteria for screening, diagnosis and referral of patients using a calculator. In the control group,
GPs will follow their usual care procedures, tools and tests. In both groups outcomes will be assessed at baseline and at 12 weeks.
What are the possible benefits and risks of participating?
The study cannot promise any benefits to participants but the information from this study will help improve the treatment of people with NAFLD/NASH.
Where is the study run from?
University of Crete (Greece)
When is the study starting and how long is it expected to run for?
May 2020 to March 2023
Who is funding the study?
Gilead Sciences (USA)
Who is the main contact?
Prof. Christos Lionis
Lionis@med.uoc.gr
Contact information
Scientific
Chief Investigator
University Campus
Voutes
Heraklion
70013
Greece
| Phone | +30 (0)2810394621 |
|---|---|
| lionis@med.uoc.gr |
Study information
| Study design | Multi-centre parallel-group randomized controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Prevention |
| Participant information sheet | Not available in web format |
| Scientific title | Evaluating a clinical care pathway for NASH/NAFLD primary care patients: a multi-centre randomized controlled trial |
| Study objectives | It is hypothesized that the proposed evidence-informed and locally adapted NASH Model of Care implemented by trained health care providers will increase the numbers of patients screened for and diagnosed with NASH in primary care (PC) and linked to specialty care compared to usual care. |
| Ethics approval(s) | Approved 23/06/2020, Research Ethics Committee University of Crete (Research Ethics Board, University of Crete, University Campus Voutes, 70013, Heraklion, Crete, Greece; +30 (0)2810 545206 (ext. 5206); ehde@uoc.gr), ref: 48/05.03.2020, 144/23.06.2020 |
| Health condition(s) or problem(s) studied | Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) |
| Intervention | Current interventions as of 15/02/2023: Twelve PC practices (four practices per country) will participate in the model evaluation. Practices will be randomized to intervention and control groups in a 1:1 ratio. From all intervention and control practices, the researchers will recruit a representative sample of patients at high risk for NFLD/NASH (obesity, type 2 diabetes or metabolic syndrome, cardiovascular disease, liver dysfunction). Intervention group: Primary care providers will be asked to implement the NAFLD/NASH model of care which includes a standardized care pathway which involves a protocol defining different HP tasks for the screening, diagnosis, referral and management of patients at high risk for NAFLD/NASH. All GPs in practices randomized to the intervention group will be exposed to NAFLD/NASH training intervention and supported by implementing the Model of Care. The NAFLD/NASH Model of Care includes screening algorithms which assess serum biomarkers and calculation of FIB-4 score (next-to-patient). Patient auto-calculation will be promoted. Patients with FIB-4 < 1.30 will be considered as having no sufficient evidence of liver fibrosis, thus not requiring referral to specialists. However, they will be advised to modify their diet and lifestyle and repeat FIB-4 every 2 years. For indeterminate FIB-4 values, patients will be referred to hospital care for transient elastography. Hospital specialists will interpret elastography results jointly with serum markers. Control group: In the control group, GPs will follow their usual care procedures, tools and tests. Previous interventions: Twelve PC practices (four practices per country) will participate in the model evaluation. Practices will be randomized to intervention and control groups in a 1:1 ratio. The randomization is computer generated by a faculty not involved in the study. From all intervention and control practices, the researchers will recruit a representative sample of patients at high risk for NASH (age >50 years, obesity, type 2 diabetes or metabolic syndrome). Intervention group: Primary care providers will be asked to implement the NASH model of care which includes a standardized care pathway which involves a protocol defining different HP tasks for the screening, diagnosis, referral and management of patients at high risk for NASH. All GPs in practices randomized to the intervention group will be exposed to NASH training intervention and supported with implementing the Model of Care. The NASH Model of Care includes Screening algorithms will include serum biomarkers and calculation of FIB-4 (next-to-patient). Patient auto-calculation will be promoted. Patients with FIB-4 < 1.30 will be considered as having no sufficient evidence of liver fibrosis, thus not requiring referral to specialists. However, they will be advised to modify their diet and lifestyle and repeat FIB-4 every 2 years. For indeterminate FIB-4 values, patients will be referred to hospital care for transient elastography. Hospital specialists will interpret elastography results jointly with serum markers. Control group: In the control group, GPs will follow their usual care procedures, tools and tests. |
| Intervention type | Other |
| Primary outcome measure | Current primary outcome measure as of 15/02/2023: The following primary outcome measures will be assessed at 12 weeks: 1. Number of patients screened for NAFLD/NASH measured using prospective tracking of eligible patients 2. Number of patients diagnosed with advanced fibrosis measured using diagnostic criteria (case report form) 3. Number of patients referred to the specialist using GP report (case report form) Previous primary outcome measure: The following primary outcome measures will be assessed at 12 weeks: 1. Number of patients screened for NASH measured using prospective tracking of eligible patients 2. Number of patients diagnosed with advanced fibrosis measured using diagnostic criteria (case report form) 3. Number of patients referred to the specialist using GP report (case report form) |
| Secondary outcome measures | Current secondary outcome measure as of 15/02/2023: The following secondary outcome measures will be assessed: 1. Proportion of patients accepting assessment at PC, measured by GP report (case report form) 2. Proportion of patients accepting referral to specialists, measured by GP report (case report form) 3. Number of patients without advanced fibrosis (F1/F2) who did not need a referral to a specialist, measured using a GP report (case report form) 4. Number of patients with advanced fibrosis (F3/F4) receiving comprehensive care, measured using standardized criteria (case report form) 5. Number of high-risk patients screened for NAFLD/NASH allocated to PC, measured using GP report (case report form) Previous secondary outcome measure: The following secondary outcome measures will be assessed at 12 weeks: 1. Proportion of patients accepting assessment at PC, measured by GP report (case report form) 2. Proportion of patients accepting referral to specialists, measured by GP report (case report form) 3. Number of patients without advanced fibrosis (F1/F2) who did not need a referral to a specialist, measured using a GP report (case report form) 4. Number of patients with advanced fibrosis (F3/F4) receiving comprehensive care, measured using standardized criteria (case report form) 5. Number of high-risk patients screened for NASH allocated to PC, measured using GP report (case report form) 6. Direct/indirect costs of model implementation, measured by cost tracking of medical and non-medical expenses |
| Overall study start date | 01/05/2020 |
| Completion date | 15/03/2023 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 600 |
| Total final enrolment | 220 |
| Key inclusion criteria | Current inclusion criteria as of 15/02/2023: 1. Metabolic dysfunction: overweight/obesity OR type 2 diabetes OR metabolic syndrome (MetS) OR 2. Liver dysfunction: raised alanine aminotransferase (ALT) OR raised aspartate aminotransferase (AST) OR 3. NAFLD: an ultrasonographic fatty liver indicator (US-FLI) >60 AND no other causes of liver disease AND no alcohol excess OR 4. Cardiovascular disease (CVD): any diagnosis or medication for CVD Previous inclusion criteria: 1. Registered as a patient in the practice of the participating GP 2. Age >=50 years 3. One or more of the following conditions: 3.1. Obesity (BMI>30) 3.2. Type 2 diabetes (T2DM) 3.3. Metabolic syndrome (MetS) |
| Key exclusion criteria | 1. Not registered in the selected GPs practice 2. Unwillingness or inability to provide signed informed consent and complete study procedures due to cognitive impairment, dementia and/or terminal illness |
| Date of first enrolment | 21/11/2022 |
| Date of final enrolment | 22/12/2022 |
Locations
Countries of recruitment
- Greece
- Spain
Study participating centres
Andrea Kalokerinou 13, Giofirakia
Heraklion
71500
Greece
Barcelona
8708007
Spain
Sponsor information
University/education
Clinic of Social and Family Medicine
School of Medicine
University Campus
Voutes
Heraklion
70013
Greece
| Phone | +30 (0)2810394621 |
|---|---|
| lionis@med.uoc.gr | |
| Website | http://www.fammed.uoc.gr/ |
"ROR" |
https://ror.org/00dr28g20 |
Funders
Funder type
Industry
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Gilead, Gilead Sciences, Inc.
- Location
- United States of America
Results and Publications
| Intention to publish date | 30/06/2023 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Results will be published in peer-reviewed medical journals and presented at professional conferences. Results will be disseminated via patient groups, on the trial webpage and publicised on social media. A summary of the results will be sent to participants who specify that they would like to receive them. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are available from the chief investigator Prof. Christos Lionis (Lionis@med.uoc.gr) on reasonable request. Data will be made available after the trial outcomes paper is published in a peer-reviewed journal; applicants must provide an as a minimum a publicly available pre-specified protocol describing the purpose, methods and analysis of the secondary research; de-identified data will be available indefinitely; consent from participants for secondary use of data will be obtained; patient identifiable data will never be shared with third parties. |
Editorial Notes
22/02/2023: The ethics approval has been updated.
15/02/2023: The following updates have been made to the study record and the plain English summary updated accordingly:
1. The trial type has been changed from Treatment to Prevention.
2. The overall trial end date has been changed from 30/08/2022 to 15/03/2023.
3. The condition has been changed from "Non-alcoholic steatohepatitis (NASH)" to "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)".
4. The interventions have been changed.
5. The primary outcome measure has been changed.
6. The secondary outcome measure has been changed.
7. The inclusion criteria have been changed.
8. Total final enrollment added.
9. The recruitment start date has been changed from 01/07/2021 to 21/11/2022.
10. The recruitment end date has been changed from 30/10/2021 to 22/12/2022.
11. Netherlands was removed from countries of recruitment.
12. Maastricht University and Maastricht University Medical Centre was removed from the trial participating centres.
06/12/2021: The following changes have been made:
1. The overall trial end date has been changed from 30/03/2022 to 30/08/2022 and the plain English summary updated accordingly.
2. The intention to publish date has been changed from 30/10/2022 to 30/06/2023.
21/05/2020: Trial's existence confirmed by Gilead Sciences.
